24. Mushahary D, Spittler A, Kasper C, Weber V, Charwat V. Isolation, cultivation, and characterization of human mesenchymal stem cells. Cytometry A. 2018;93(1):19-31.
25. Sun Y. Zhao J. Zhang L, et al. Effectiveness and safety of stem cell therapy for diabetic foot: a meta-analysis update. Stem Cell Res Ther. 2022;13(1):416.
26. Lu D, Chcen B, Linag Z, et al. Comparison of bone marrow mesenchymal stem cells with bone marrow-derived mononuclear cells for treatment of diabetic critical limb ischemia and foot ulcer: a double- blind, randomized, controlled trial. Diabetes Res Clin Pract. 2011;92(1):26-36.
27. Medina RJ, Barber CL, Sabatier F, et al. Endothelial Progenitors: A Consensus Statement on Nomenclature. Stem Cells Transl Med. 2017; 6(5):1316-1320.
28. Sullivan, R, Dailey T, Duncan K, et al. Peripheral Nerve Injury: Stem Cell Therapy and Peripheral Nerve Transfer. Int J Mol Sci. 2016;17(12):2101. Dostupné z DOI <https://doi.org/10.3390/ijms17122101>
29. Fuentealba LC, Obernier K, and Alvarez-Buylla A. Adult Neural Stem Cells Bridge Their Niche. Cell Stem Cell. 2012;10(6):698-708.
30. Kaneko N, Kako E, and Sawamoto K. Prospects and Limitations of Using Endogenous Neural Stem Cells for Brain Regeneration. Genes (Basel). 2011;2(1):107-30.
31. Muir K, Bulters D, Willmot M. Intracerebral implantation of human neural stem cells and motor recovery after stroke: multicentre prospective single-arm study (PISCES-2). J Neurol Neurosurg Psychiatry. 2020;91(4):396-401.
32. Cui CH, Uyama, T, Miyado K, et al. Menstrual Blood-Derived Cells Confer Human Dystrophin Expression in the Murine Model of Duchenne Muscular Dystrophy via Cell Fusion and Myogenic Transdifferentiation. Mol Biol Cell. 2007;18(5):1586-94.
33. Asahara T, Murohara T, Sullivan A, et al. Isolation of putative progenitor endothelial cells for angiogenesis. Science. 1997;275(5302):964-7.
34. Göthert JR, Gustin SE, van Eekelen JA, et al. Genetically tagging endothelial cells in vivo: bone marrow-derived cells do not contribute to tumor endothelium. Blood. 2004;104(6):1769-77.
35. Purhonen S, Palm J, Rossi D, et al. Bone marrow-derived circulating endothelial precursors do not contribute to vascular endothelium and are not needed for tumor growth. Proc Natl Acad Sci U S A. 2008; 105(18):6620-5.
36. Bergers G, Song S. The role of pericytes in blood-vessel formation and maintenance. Neuro Oncol. 2005;7(4):452-64.
37. Dong Z, Chen B, Fu W, et al. Transplantation of purified CD34+ cells in the treatment of critical limb ischemia. J Vasc Surg. 2013;58(2):404-411.
38. Klepanec A, Mistrík M, Altaner C. No difference in intra-arterial and intramuscular delivery of autologous bone marrow cells in patients with advanced critical limb ischemia. Cell Transplant. 2012;21(9):1909-18.
39. Hsu SL, Yin TC, Shao PL, et al. Hyperbaric oxygen facilitates the effect of endothelial progenitor cell therapy on improving outcome of rat critical limb ischemia. Am J Transl Res. 2019;11(4):1948-1964.
40. Fejfarová V, Matuška J, Jude E, et al. Stimulation TcPO2 Testing Improves Diagnosis of Peripheral Arterial Disease in Patients With Diabetic Foot. Front Endocrinol (Lausanne). 2021; 12. Available from: DOI <https://doi.org/10.3389/fendo.2021.744195>
41. Baláž D, Komorníková A, Sabaka P, et al. Význam transkutánneho monitorovania tkanivového kyslíka u pacienta s diabetes mellitus s jeho komplikáciami. Vnitř Lék. 2015;61(2):106-113.
42. Hájek M, Šedivý P, Kovář J, et al. Dynamická in vivo 31P MR spektroskopie člověka. Chem. Listy. 2017;111:516-523.
43. Dubský M, Husáková J, Bém R, et al. Comparison of the impact of autologous cell therapy and conservative standard treatment on tissue oxygen supply and course of the diabetic foot in patient with chronic limb- ischemia: A randomized controlled trial. Front Endocrinol (Lausanne). 2022; 29. Available from: DOI <https://doi.org/10.3389/fendo.2022.888809>
44. Tateishi-Yuyama E, Matsubara H, Murohara T, et al. Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: A pilot study and a randomised controlled trial. Lancet. 2002;360 (9331):427-35.
45. Matoba S, Tatsumi T, Murohara T, et al. Long-term clinical outcome after intramuscular implantation of bone marrow mononuclear cells (Therapeutic Angiogenesis by Cell Transplantation [TACT] trial) in patients with chronic limb ischemia. Am Heart J. 2008;156(5):1010-8.
46. Walter DH, Krankenberg H, Balzer J, et al. Intraarterial Administration of Bone Marrow Mononuclear Cells in Patients With Critical Limb Ischemia. A Randomized-Start, Placebo-Controlled Pilot Trial (PROVASA). Circ Cardiovasc Interv. 2011;4(1):26-37.
47. Teraa M, Sprengers RW, Schutgens REG, et al. Effect of repetitive intra-arterial infusion of bone marrow mononuclear cells in patients with no-option limb ischemia: the randomized, double-blind, placebo-controlled Rejuvenating Endothelial Progenitor Cells via Transcutaneous Intra-arterial Supplement. Circulation. 2015;131(10):851-60.
48. Pu H. Huang Q, Zhang X. A meta-analysis of randomized controlled trials on therapeutic efficacy and safety of autologous cell therapy for atherosclerosis obliterans. J Vasc Surg. 2022;75(4):1440-1449.
49. Murphy MP, Lawson JH, Rapp BM, et al. Autologous bone marrow mononuclear cell therapy is safe and promotes amputation-free survival in patients with critical limb ischemia. J Vasc Surg. 2011;53(6):1565-74.